WHAT ARE PEPTIDES? A PLAIN ENGLISH EXPLAINER

Amino acids are organic molecules with a central carbon atom, an amino group (NH2), a carboxyl group (COOH), and a variable side chain that determines each amino acid's unique properties. There are 20 standard amino acids used in human biology. When two amino acids bond, the amino group of one connects to the carboxyl group of another — releasing water and forming a peptide bond. A chain of two is a dipeptide; three is a tripeptide; chains up to roughly 50 amino acids are generally classified as peptides; longer chains are proteins.

The distinction between peptides and proteins isn't perfectly clean — there's no universal consensus on exactly where the boundary falls — but for biological function, the key difference is structural. Peptides are generally too short to fold into stable three-dimensional structures and tend to act as direct molecular signals, while proteins form complex functional structures (enzymes, receptors, structural fibers). This makes peptides smaller, easier to synthesize, and in some cases more easily administered than proteins.

Peptides function as signaling molecules by binding to specific receptors on cell surfaces and triggering downstream effects inside the cell. A GLP-1 receptor agonist binds to GLP-1 receptors on pancreatic beta cells, hypothalamic neurons, and gastric tissue — producing insulin secretion, reduced appetite, and slowed gastric emptying. A GHRH analog (like CJC-1295) binds to growth hormone-releasing hormone receptors in the pituitary, triggering GH secretion. BPC-157 appears to interact with multiple receptor pathways simultaneously, including VEGF receptors and nitric oxide signaling pathways.

The specificity of peptide-receptor binding is what makes them pharmacologically powerful. The body already has systems designed to respond to peptide signals; synthetic peptides are exploiting existing receptor pathways rather than introducing entirely foreign mechanisms. This is also why the line between a pharmaceutical drug and a 'research compound' is often a regulatory designation rather than a fundamental biological distinction.

Anabolic steroids are small molecule lipid compounds — they cross cell membranes directly and interact with intracellular receptors, altering gene expression systemically. They suppress the body's natural hormone production through negative feedback. Taking exogenous testosterone suppresses LH and FSH secretion, which suppresses endogenous testosterone production. This is suppression — the body detects that hormone levels are sufficient and stops producing them.

Exogenous HGH (human growth hormone) replaces the body's natural GH production. The pituitary detects elevated GH and reduces its own output. Pulsatility is lost; feedback mechanisms are bypassed.

GH secretagogues — ipamorelin, CJC-1295, GHRP-6 — work differently. They stimulate the pituitary to produce more of your own GH, through your own biology. Natural pulsatility is preserved. Negative feedback mechanisms remain intact, which prevents indefinite escalation. The ceiling on GH output is your own pituitary's capacity, not an external dose. This is the pharmacological reason that GH secretagogues have a fundamentally different risk profile from exogenous HGH.

A poorly manufactured vitamin supplement is usually just ineffective. A poorly manufactured injectable peptide can be actively harmful. The difference is the route of administration: injecting a compound with bacterial endotoxin contamination, residual synthesis solvents, or microbial contamination bypasses the natural filtering systems of the gut and delivers those contaminants directly into subcutaneous tissue.

This is not theoretical. Endotoxin contamination in injectable products can cause fever, chills, and in severe cases systemic inflammatory responses. Residual synthesis solvents are bioactive compounds with their own toxicology profiles. The FDA requires injectable pharmaceuticals to meet strict endotoxin, sterility, and purity standards for this reason. Research peptides operate outside that regulatory framework, which makes source selection one of the most important risk management decisions in any protocol.